线粒体质量控制:糖尿病肾病治疗的新靶点
本文综述线粒体质量控制(MQC)在糖尿病肾病(DKD)中的作用。DKD影响超过40%的糖尿病患者,是终末期肾病(ESRD)的首要病因。线粒体功能障碍导致ATP减少、损伤线粒体堆积和ROS增加,促进肾脏恶化;维持MQC对防止细胞死亡和肾衰竭至关重要。近期临床试验显示增强MQC可缓解DKD,但现有治疗无法阻止肾功能下降,线粒体靶向药物有潜力但存在不良反应和机制不明等挑战。
要点
- DKD影响超过40%的糖尿病患者,是ESRD首要病因。
- 线粒体功能障碍导致ATP减少、损伤线粒体堆积和ROS增加,促进肾脏恶化。
- 增强MQC可缓解DKD,但线粒体靶向药物存在不良反应和机制不明等挑战。
核心结论
- MQC在DKD治疗中具有重要意义,维持线粒体质量是开发新疗法的关键。
研究设计与样本
- 本文为综述,未报告系统检索范围。
主要发现
- DKD影响超过40%的糖尿病患者,是ESRD的首要病因。
- 线粒体功能障碍导致ATP产生减少、损伤线粒体堆积和ROS增加,促进肾脏恶化。
- 维持MQC对防止细胞死亡、组织损伤和肾衰竭至关重要。
- 近期临床试验显示增强MQC可缓解DKD。
- 现有治疗无法阻止肾功能下降,线粒体靶向药物有潜力但存在不良反应和机制不明等挑战。
临床怎么用
- 未来研究应全面探索MQC在DKD中的治疗潜力。
局限性
- 线粒体靶向药物存在不良反应和机制不明等挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD), affecting over 40% of patients with diabetes. DKD progression involves fibrosis and damage to glomerular and tubulointerstitial regions, with mitochondrial dysfunction playing a critical role. Impaired mitochondria lead to reduced adenosine triphosphate (ATP) production, damaged mitochondria accumulation, and increased reactive oxygen species (ROS), contributing to renal deterioration. Maintaining mitochondrial quality control (MQC) is essential for preventing cell death, tissue injury, and kidney failure. Recent clinical trials show that enhancing MQC can alleviate DKD. However, current treatments cannot halt kidney function decline, underscoring the need for new therapeutic strategies. Mitochondrial-targeted drugs show potential; however, challenges remain because of adverse effects and unclear mechanisms. Future research should aim to comprehensively explore therapeutic potential of MQC in DKD. This review highlights the significance of MQC in DKD treatment, emphasizing the need to maintain mitochondrial quality for developing new therapies.
引用
- Li Q, Shang J, Inagi R, et al. Control of Mitochondrial Quality: A Promising Target for Diabetic Kidney Disease Treatment. Kidney Int Rep. 2024. PMID: 40303215. doi:10.1016/j.ekir.2024.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。